LOUISVILLE, Ky., Aug. 04, 2026 (GLOBE NEWSWIRE) — Creative Realities, Inc. (“Creative Realities,” “CRI,” or the “Company”) (NASDAQ: CREX), a leading provider of digital signage and media solutions, announced today that it will release its financial results for the three months ended June 30, 2026 before the market open on Thursday, August 13, 2026. A conference call to review the results is scheduled for Thursday, August 13, 2026, at 9:00 am Eastern Time, which will include prepared remarks and materials from management followed by a live Q&A. The call will be hosted by Rick Mills, Chairman and Chief Executive Officer, Tamra Koshewa, Chief Financial Officer and George Sautter, Chief Strategy Officer. Prior to the call, participants should register at https://bit.ly/CREXearnings2Q2026. Once...

First module of the rolling NDA for QTORIN™ rapamycin for microcystic lymphatic malformations submitted to FDA, with completion of the NDA submission on track for the second half of 2026 Preparing for a planned standalone U.S. commercial launch of QTORIN™ rapamycin for microcystic lymphatic malformations in the first half of 2027, if approved Initiation of Phase 3 trial of QTORIN™ rapamycin for the treatment of cutaneous venous malformations planned for the fourth quarter of 2026 Initiation of Phase 2 trial of QTORIN™ pitavastatin for the treatment of disseminated superficial actinic porokeratosis planned for the second half of 2026 Topline results from the Phase 2 LOTU trial of QTORIN™ rapamycin for clinically significant angiokeratomas expected in the second half of 2027 Cash, cash equivalents and short-term...

WAKIX® Net Revenue Grew 30% Year over Year to $261.3 Million for Second Quarter 2026; Estimated Average Patients Increased 450 to 8,950; Reiterates 2026 WAKIX Net Revenue Guidance of $1.0 Billion to $1.04 Billion Phase 1 SAD Data for BP-205 Demonstrate Favorable PK and Safety/Tolerability Profiles; Phase 1 MAD Data Expected in Q4 2026 BP-205 IND Open in US; Initiating Phase 1b Study in Sleep-Deprived Healthy Volunteers in Q3; Data Expected Early 2027 Initiating Phase 2 Trials for BP-205 in Mid-2027 to Evaluate Multiple CNS Indications Pitolisant GR NDA Accepted in July; Target PDUFA Date April 1, 2027 Pitolisant HD On Track for Phase 3 Topline Data in 2027 and Target PDUFA Date in 2028 Conference Call and Webcast Today at 8:30 a.m. ET PLYMOUTH MEETING, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) — Harmony Biosciences Holdings, Inc. (Nasdaq:...

July trading volume reached 785,129 contracts, increasing 127% over June Average daily open interest reached 1,199 in July, 83% above the Q2 2026 average Abaxx Exchange surpassed 100,000 contracts traded in a single day for the first time on July 1, with July ADV reaching 34,136 contracts per day, 134% above the Q2 2026 averageTORONTO, Aug. 04, 2026 (GLOBE NEWSWIRE) — Abaxx Technologies Inc. (TSX:ABXX)(OTCQX:ABXXF) (“Abaxx” or the “Company”), a financial software and market infrastructure company, majority shareholder of Abaxx Singapore Pte Ltd., the owner of Abaxx Commodity Exchange and Clearinghouse (individually, “Abaxx Exchange” and “Abaxx Clearing”), today reported that monthly trading volume on Abaxx Exchange more than doubled in July 2026. July trading volume more than doubled over June, with ADV exceeding 34,000 contracts...

Strategic partnership advances the introduction of a new class of autonomous aircraft, Canadian manufacturing and sovereign industrial capability VAUGHAN, Ontario, Aug. 04, 2026 (GLOBE NEWSWIRE) — Volatus Aerospace Inc. (TSX: FLT) (OTCQX: TAKOF) (Frankfurt: ABB.F) (“Volatus” or the “Company”), a Canadian-headquartered global aerospace and defence company, today announced the next phase of its national wildfire response initiative through a Strategic Partnership with Singular Aircraft S.L. (“Singular”), developer of the FlyOx 1 multi-mission heavy-lift autonomous aircraft platform. The agreement establishes Volatus as Singular’s Canadian Strategic Partner and creates the framework for introducing the FlyOx 1 into Canada while evaluating Canadian manufacturing, systems integration, operational deployment and long-term in-country...

Männedorf, Switzerland, August 4, 2026 – The Tecan Group AG (SIX Swiss Exchange: TECN) will hold a conference call to discuss the financial results for the first half year 2026 on Tuesday, August 11th, 2026, at 09:00 CEST. The results will be published on August 11th, 2026, at 7:00 CEST. The conference call will be audio-webcast with synchronized presentation slides. The webcast and a replay of the webcast will be made available in the “Investor Relations” section of Tecan’s website www.tecan.com. Interested parties can also listen to the conference call by phone. The dial-in numbers for the call are as follows:Participants from Europe: +41 (0) 58 310 50 00 or +44 (0) 203 059 58 63 Participants from the U.S.: +1 (1) 631 570 56 13Participants should if possible dial in 15 minutes before the start of the event. On August...

Switchtec™ PCIe Switches and Micron® 9650 NVMe® solid state drives (SSDs) leverage next generation interface technology to deliver increased bandwidth, low latency, and scalable storage connectivity CHANDLER, Ariz., Aug. 04, 2026 (GLOBE NEWSWIRE) — Microchip Technology (Nasdaq: MCHP) today announced a demonstration showcasing an end‑to‑end PCIe® Gen 6 storage architecture, combining Microchip’s Switchtec™ PCIe Gen 6 switches with high-performance Micron 9650 NVMe® solid state drives (SSDs). The demonstration highlights the role of next‑generation PCIe technology in enabling higher data throughput, reduced latency and scalable connectivity for AI, high‑performance computing (HPC) and cloud data center workloads. At the 2026 Future of Memory and Storage (FMS) Conference, the demonstration features a Microchip Switchtec...